Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

shanghai pharmaceuticals - SHPMY

SHPMY

Close Chg Chg %
6.83 0.65 9.52%

Closed Market

7.48

+0.65 (9.52%)

Volume: 272.00

Last Updated:

Jul 11, 2025, 2:26 PM EDT

Trade Now

Company Overview: shanghai pharmaceuticals - SHPMY

SHPMY Key Data

Open

$7.48

 Day Range

7.48 - 7.48

52 Week Range

5.96 - 9.44

 Market Cap

$1.44B

Shares Outstanding

183.81M

 Public Float

N/A

Beta

0.64

 Rev. Per Employee

N/A

P/E Ratio

9.63

 EPS

$0.81

Yield

311.13%

 Dividend

$0.14

EX-DIVIDEND DATE

Jul 17, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

17.50

  

SHPMY Performance

1 Week
 
 9.52%
 
1 Month
 
 2.19%
 
3 Months
 
 -4.65%
 
1 Year
 
 -1.84%
 
5 Years
 
 N/A
 

SHPMY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Shanghai Pharmaceuticals - SHPMY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
33.36B 34.34B 36.63B 38.14B
Sales Growth
+20.36% +2.95% +6.67% +4.10%
Cost of Goods Sold (COGS) incl D&A
29.23B 30.15B 32.54B 34.23B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
360.76M 326.88M 333.27M 360.43M
Depreciation
265.74M 269.13M 252.40M 278.31M
Amortization of Intangibles
66.04M 57.76M 53.72M 55.57M
COGS Growth
+21.50% +3.17% +7.90% +5.20%
Gross Income
4.13B 4.19B 4.10B 3.91B
Gross Income Growth
+12.88% +1.38% -2.20% -4.56%
Gross Profit Margin
+12.39% +12.20% +11.19% +10.25%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.98B 2.99B 2.90B 2.68B
Research & Development
283.36M 288.11M 282.11M 300.43M
Other SG&A
2.70B 2.70B 2.62B 2.38B
SGA Growth
+16.61% +0.32% -3.11% -7.47%
Other Operating Expense
7.98M 1.35M 43.75M 19.34M
Unusual Expense
47.15M 21.32M (18.02M) 44.66M
EBIT after Unusual Expense
1.10B 1.18B 1.17B 1.17B
Non Operating Income/Expense
290.51M 316.31M 79.21M 151.32M
Non-Operating Interest Income
53.88M 65.10M 67.44M 78.06M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
247.10M 263.30M 276.50M 275.57M
Interest Expense Growth
+14.74% +6.56% +5.01% -0.34%
Gross Interest Expense
247.10M 263.30M 276.50M 275.57M
Interest Capitalized
- - - -
-
Pretax Income
1.14B 1.23B 977.41M 1.04B
Pretax Income Growth
+27.65% +7.85% -20.53% +6.59%
Pretax Margin
+3.42% +3.58% +2.67% +2.73%
Income Tax
289.83M 269.74M 266.44M 298.74M
Income Tax - Current - Domestic
264.36M 289.34M 294.68M 312.91M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
25.47M (19.61M) (28.24M) (14.16M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
972.90M 1.04B 729.22M 815.64M
Minority Interest Expense
183.13M 204.18M 197.40M 183.06M
Net Income
789.76M 834.18M 531.83M 632.58M
Net Income Growth
+21.24% +5.62% -36.25% +18.94%
Net Margin Growth
+2.37% +2.43% +1.45% +1.66%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
789.76M 834.18M 531.83M 632.58M
Preferred Dividends
- - - -
-
Net Income Available to Common
789.76M 834.18M 531.83M 632.58M
EPS (Basic)
1.3894 1.1976 0.7184 0.8539
EPS (Basic) Growth
+21.24% -13.80% -40.01% +18.86%
Basic Shares Outstanding
568.42M 696.55M 740.26M 740.81M
EPS (Diluted)
1.3894 1.1976 0.7184 0.8539
EPS (Diluted) Growth
+21.24% -13.80% -40.01% +18.86%
Diluted Shares Outstanding
568.42M 696.55M 740.26M 740.81M
EBITDA
1.50B 1.53B 1.49B 1.57B
EBITDA Growth
+9.11% +1.35% -2.30% +5.45%
EBITDA Margin
+4.51% +4.44% +4.07% +4.12%

Shanghai Pharmaceuticals in the News